

Cesar Munoz-Fontela

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11549917/publications.pdf>

Version: 2024-02-01

45
papers

4,069
citations

201575

27
h-index

233338

45
g-index

45
all docs

45
docs citations

45
times ranked

8428
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances and gaps in SARS-CoV-2 infection models. PLoS Pathogens, 2022, 18, e1010161.	2.1	61
2	Zaire ebolavirus surveillance near the Bikoro region of the Democratic Republic of the Congo during the 2018 outbreak reveals presence of seropositive bats. PLoS Neglected Tropical Diseases, 2022, 16, e0010504.	1.3	5
3	SARS-CoV-2 Variants and Vaccines. New England Journal of Medicine, 2021, 385, 179-186.	13.9	322
4	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. European Journal of Medicinal Chemistry, 2021, 223, 113654.	2.6	10
5	Animal models for COVID-19. Nature, 2020, 586, 509-515.	13.7	705
6	Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins. Viruses, 2020, 12, 915.	1.5	13
7	Severe Human Lassa Fever Is Characterized by Nonspecific T-Cell Activation and Lymphocyte Homing to Inflamed Tissues. Journal of Virology, 2020, 94, .	1.5	14
8	Long-term wildlife mortality surveillance in northern Congo: a model for the detection of Ebola virus disease epizootics. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180339.	1.8	14
9	Regulation of the Ebola Virus VP24 Protein by SUMO. Journal of Virology, 2019, 94, .	1.5	19
10	Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice. JCI Insight, 2019, 4, .	2.3	26
11	Immune barriers of Ebola virus infection. Current Opinion in Virology, 2018, 28, 152-160.	2.6	25
12	T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans. Journal of Infectious Diseases, 2018, 218, S508-S518.	1.9	25
13	Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease. Journal of Infectious Diseases, 2018, 218, S496-S503.	1.9	25
14	Outbreaks in a Rapidly Changing Central Africa – Lessons from Ebola. New England Journal of Medicine, 2018, 379, 1198-1201.	13.9	56
15	Comprehensive characterization of cellular immune responses following Ebola virus infection. Journal of Infectious Diseases, 2017, 215, jiw508.	1.9	38
16	Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biology, 2017, 18, 4.	3.8	115
17	Humanized Mice Reproduce Acute and Persistent Human Adenovirus Infection. Journal of Infectious Diseases, 2017, 215, 70-79.	1.9	15
18	The gap between animal and human Ebola virus disease. Future Virology, 2017, 12, 61-65.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination. <i>Scientific Reports</i> , 2017, 7, 43776.	1.6	31
20	Ebola Virus Disease in Humans: Pathophysiology and Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 141-169.	0.7	31
21	Monocyte-derived dendritic cells enhance protection against secondary influenza challenge by controlling the switch in CD8 ⁺ T cell immunodominance. <i>European Journal of Immunology</i> , 2017, 47, 345-352.	1.6	13
22	Different features of $\gamma\delta$ T and NK cells in fatal and non-fatal human Ebola infections. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005645.	1.3	46
23	Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. <i>PLoS Pathogens</i> , 2016, 12, e1005656.	2.1	41
24	Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. <i>Science</i> , 2016, 352, aad7993.	6.0	132
25	Unique human immune signature of Ebola virus disease in Guinea. <i>Nature</i> , 2016, 533, 100-104.	13.7	170
26	Emerging roles of p53 and other tumour-suppressor genes in immune regulation. <i>Nature Reviews Immunology</i> , 2016, 16, 741-750.	10.6	262
27	Cell senescence is an antiviral defense mechanism. <i>Scientific Reports</i> , 2016, 6, 37007.	1.6	70
28	Cytokine kinetics of Zika virus-infected patients from acute to convalescent phase. <i>Medical Microbiology and Immunology</i> , 2016, 205, 269-273.	2.6	142
29	KSHV latent protein LANA2 inhibits sumo2 modification of p53. <i>Cell Cycle</i> , 2015, 14, 277-282.	1.3	17
30	Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. <i>Nature</i> , 2015, 524, 97-101.	13.7	272
31	Zika virus infections imported to Italy: Clinical, immunological and virological findings, and public health implications. <i>Journal of Clinical Virology</i> , 2015, 63, 32-35.	1.6	158
32	Mucosal Polyinosinic-Polycytidylic Acid Improves Protection Elicited by Replicating Influenza Vaccines via Enhanced Dendritic Cell Function and T Cell Immunity. <i>Journal of Immunology</i> , 2014, 193, 1324-1332.	0.4	42
33	Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. <i>Antiviral Research</i> , 2014, 105, 17-21.	1.9	428
34	SUMOylation of p53 mediates interferon activities. <i>Cell Cycle</i> , 2013, 12, 2809-2816.	1.3	23
35	Estrogen Mediates Innate and Adaptive Immune Alterations to Influenza Infection in Pregnant Mice. <i>PLoS ONE</i> , 2012, 7, e40502.	1.1	74
36	Acetylation is indispensable for p53 antiviral activity. <i>Cell Cycle</i> , 2011, 10, 3701-3705.	1.3	41

#	ARTICLE	IF	CITATIONS
37	p53 Serves as a Host Antiviral Factor That Enhances Innate and Adaptive Immune Responses to Influenza A Virus. <i>Journal of Immunology</i> , 2011, 187, 6428-6436.	0.4	77
38	Dual Role of p53 in Innate Antiviral Immunity. <i>Viruses</i> , 2010, 2, 298-313.	1.5	101
39	Kaposi's Sarcoma-Associated Herpesvirus Protein LANA2 Disrupts PML Oncogenic Domains and Inhibits PML-Mediated Transcriptional Repression of the Survivin Gene. <i>Journal of Virology</i> , 2009, 83, 8849-8858.	1.5	75
40	Transcriptional role of p53 in interferon-mediated antiviral immunity. <i>Journal of Experimental Medicine</i> , 2008, 205, 1929-1938.	4.2	205
41	Control of virus infection by tumour suppressors. <i>Carcinogenesis</i> , 2007, 28, 1140-1144.	1.3	9
42	Novel and unexpected role for the tumor suppressor ARF in viral infection surveillance. <i>Future Virology</i> , 2007, 2, 625-629.	0.9	1
43	Antiviral action of the tumor suppressor ARF. <i>EMBO Journal</i> , 2006, 25, 4284-4292.	3.5	43
44	Resistance to viral infection of super p53 mice. <i>Oncogene</i> , 2005, 24, 3059-3062.	2.6	66
45	Characterization of the bipartite nuclear localization signal of protein LANA2 from Kaposi's sarcoma-associated herpesvirus. <i>Biochemical Journal</i> , 2003, 374, 545-550.	1.7	10